Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 09:57AM ET
5.31
Dollar change
-0.02
Percentage change
-0.38
%
Index- P/E- EPS (ttm)-0.85 Insider Own13.11% Shs Outstand149.34M Perf Week5.35%
Market Cap79.27M Forward P/E- EPS next Y-4.48 Insider Trans0.00% Shs Float12.98M Perf Month-10.01%
Income-126.91M PEG- EPS next Q-1.45 Inst Own27.50% Short Float1.32% Perf Quarter12.45%
Sales19.87M P/S3.99 EPS this Y-21.36% Inst Trans- Short Ratio1.80 Perf Half Y11.78%
Book/sh0.54 P/B9.80 EPS next Y43.21% ROA-70.68% Short Interest0.17M Perf Year-23.76%
Cash/sh6.91 P/C0.77 EPS next 5Y- ROE-98.26% 52W Range2.23 - 11.10 Perf YTD-15.04%
Dividend Est.- P/FCF- EPS past 5Y4.02% ROI-131.79% 52W High-52.16% Beta2.05
Dividend TTM- Quick Ratio3.67 Sales past 5Y14.80% Gross Margin- 52W Low137.57% ATR (14)0.53
Dividend Ex-Date- Current Ratio3.70 EPS Y/Y TTM-37.65% Oper. Margin-632.34% RSI (14)49.15 Volatility7.55% 11.62%
Employees228 Debt/Eq0.28 Sales Y/Y TTM-54.39% Profit Margin-638.78% Recom1.00 Target Price4.50
Option/ShortYes / Yes LT Debt/Eq0.19 EPS Q/Q-59.53% Payout- Rel Volume1.47 Prev Close5.33
Sales Surprise7.07% EPS Surprise13.48% Sales Q/Q-85.76% EarningsMar 28 BMO Avg Volume95.34K Price5.31
SMA20-2.70% SMA50-4.69% SMA2001.80% Trades Volume16,244 Change-0.38%
Date Action Analyst Rating Change Price Target Change
Dec-12-22Initiated H.C. Wainwright Buy $6
Oct-10-22Downgrade Stifel Buy → Hold $9 → $2
Aug-18-22Resumed Wells Fargo Overweight
Mar-31-22Initiated Piper Sandler Overweight $7
Feb-23-22Initiated Cantor Fitzgerald Overweight $12
Oct-21-21Initiated Truist Buy $10
Sep-30-21Initiated Stifel Buy $12
Mar-31-21Initiated Credit Suisse Outperform $15
Mar-28-19Initiated SVB Leerink Outperform
Aug-28-18Upgrade Jefferies Hold → Buy
Today 06:30AM
Mar-21-24 06:30AM
Mar-14-24 12:00PM
Mar-06-24 03:36PM
06:30AM
04:05PM Loading…
Jan-08-24 04:05PM
08:00AM
Jan-03-24 06:30AM
Dec-19-23 09:08AM
Dec-11-23 06:02AM
06:00AM
03:18AM
Dec-04-23 06:30AM
Nov-20-23 08:51AM
Nov-14-23 06:38AM
06:30AM Loading…
06:30AM
Nov-09-23 06:30AM
Nov-07-23 06:30AM
Nov-03-23 12:05PM
Nov-02-23 09:05AM
Nov-01-23 06:30AM
Oct-31-23 07:12PM
Oct-25-23 09:35AM
Oct-04-23 06:30AM
Sep-27-23 09:05AM
Sep-21-23 06:30AM
Sep-12-23 06:30AM
Sep-07-23 06:30AM
Aug-23-23 12:11PM
06:00AM
05:00AM Loading…
Aug-22-23 05:00AM
Aug-10-23 07:50AM
06:42AM
06:30AM
Aug-09-23 06:02AM
Aug-04-23 04:51PM
Aug-03-23 06:30AM
Jul-31-23 05:05PM
Jun-22-23 06:30AM
Jun-09-23 05:59PM
Jun-06-23 07:51AM
Jun-03-23 09:00AM
May-30-23 06:30AM
May-25-23 05:00PM
May-23-23 07:45AM
06:37AM
06:30AM
06:15AM
May-22-23 06:30AM
May-16-23 06:30AM
May-11-23 10:05AM
May-05-23 06:14AM
Apr-26-23 10:00AM
Apr-17-23 04:05PM
Apr-16-23 03:00PM
Apr-06-23 04:05PM
Mar-30-23 08:19AM
Mar-29-23 06:30AM
Mar-27-23 06:21AM
Mar-23-23 07:45AM
06:30AM
Mar-16-23 06:30AM
Mar-14-23 04:30PM
Mar-09-23 05:00AM
Feb-22-23 06:30AM
Feb-21-23 05:00AM
Feb-08-23 06:30AM
Jan-09-23 06:30AM
Dec-28-22 06:41AM
Dec-22-22 06:30AM
Dec-16-22 09:35AM
Dec-12-22 01:01PM
10:00AM
05:50AM
Dec-10-22 03:00PM
02:20PM
Dec-01-22 04:05PM
Nov-17-22 04:01PM
05:17AM
Nov-15-22 07:45AM
06:30AM
Nov-07-22 08:05AM
Nov-04-22 06:30AM
Nov-03-22 09:15AM
09:05AM
Nov-02-22 10:01AM
Nov-01-22 06:30AM
Oct-31-22 07:20PM
Oct-21-22 08:18AM
Oct-10-22 06:42PM
Oct-05-22 08:05AM
Sep-12-22 06:24AM
Sep-04-22 06:05PM
Sep-01-22 06:30AM
Aug-24-22 07:58AM
Aug-20-22 08:48AM
Aug-11-22 08:30AM
07:45AM
06:30AM
Aug-04-22 06:30AM
Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.